Summary
Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterfly’s innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctor’s office, under local anaesthesia.
Butterfly’s unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms. Implant doesn’t require any resection, cutting, or ablation of prostatic tissue.
FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.
Butterfly’s unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms. Implant doesn’t require any resection, cutting, or ablation of prostatic tissue.
FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190156124 |
| Start date: | 01-09-2023 |
| End date: | 31-08-2025 |
| Total budget - Public funding: | 4 823 931,25 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterfly’s innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctor’s office, under local anaesthesia.Butterfly’s unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms. Implant doesn’t require any resection, cutting, or ablation of prostatic tissue.
FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.
Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
